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Abstract
Few studies had investigated genome-wide methylation in glioblastoma multiforme (GBM). Our goals were to study
differential methylation across the genome in gene promoters using an array-based method, as well as repetitive elements
using surrogate global methylation markers. The discovery sample set for this study consisted of 54 GBM from Columbia
University and Case Western Reserve University, and 24 brain controls from the New York Brain Bank. We assembled a
validation dataset using methylation data of 162 TCGA GBM and 140 brain controls from dbGAP. HumanMethylation27
Analysis Bead-Chips (Illumina) were used to interrogate 26,486 informative CpG sites in both the discovery and validation
datasets. Global methylation levels were assessed by analysis of L1 retrotransposon (LINE1), 5 methyl-deoxycytidine (5m-dC)
and 5 hydroxylmethyl-deoxycytidine (5hm-dC) in the discovery dataset. We validated a total of 1548 CpG sites (1307 genes)
that were differentially methylated in GBM compared to controls. There were more than twice as many hypomethylated
genes as hypermethylated ones. Both the discovery and validation datasets found 5 tumor methylation classes. Pathway
analyses showed that the top ten pathways in hypomethylated genes were all related to functions of innate and acquired
immunities. Among hypermethylated pathways, transcriptional regulatory network in embryonic stem cells was the most
significant. In the study of global methylation markers, 5m-dC level was the best discriminant among methylation classes,
whereas in survival analyses, high level of LINE1 methylation was an independent, favorable prognostic factor in the
discovery dataset. Based on a pathway approach, hypermethylation in genes that control stem cell differentiation were
significant, poor prognostic factors of overall survival in both the discovery and validation datasets. Approaches that
targeted these methylated genes may be a future therapeutic goal.
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Introduction
Cancers are now recognized as driven as much by epigenetic as
well as genetic changes [1]. Among epigenetic alterations that
occur during oncogenesis, aberrant gene promoter hypermethyla-
tion is the most commonly investigated. However, there have been
few studies that evaluated differential promoter methylation across
the entire genome in glioblastoma multiforme (GBM), which is the
most common type of malignant brain tumors in adults [2–5]. The
primary goal of some studies, such as the Cancer Genome Altas
Project (TCGA), was to characterize methylation patterns in
tumors and to correlate with other genomic alterations such as
gene mutations, copy number alterations and expression [6]. The
investigation of differential methylation poses a challenge, because
unlike colon, breast or prostate cancers, it is not possible to obtain
matching ‘‘normal’’ tissues during surgery for GBM. The
alternative method, which is to procure a substantial number of
unrelated normal brain tissues for comparison, is also challenging.
Moreover, previous reports on genome-wide methylation in
normal brain tissues showed methylation patterns varied between
neuro-anatomically distinct regions, and methylation level may
change in the brain with increasing age [7–9]. Thus, an accurate
profile of differential methylation will require appropriate control
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tissues with age and neuro-anatomical distribution matching those
of glioma subjects.
Compared to genome-wide methylation near gene promoters,
methylation derangement in the repetitive elements of the GBM
genome was even less studied. Repetitive elements may comprise
over two-thirds of the human genome, and a high proportion of
them are retrotransposons, whose expression is normally sup-
pressed by methylation of cytosine [10]. Retrotransposons become
hypomethylated early on in oncogenesis. This can lead to
transposable elements insertion, and some of them, such as L1,
can express their RNAs, which then promote DNA damage,
spreading of methylation to promoters and genomic deletions
[11,12]. Despite their abundance and importance in tumorigen-
esis, the sequences and maps of repetitive elements in the genome
have been difficult to ascertain, because repeats created ambigu-
ities in alignment and in genome assembly [13]. Nevertheless,
surrogate markers that estimate global cytosine methylation
content, which indirectly reflects methylation levels in repetitive
elements due to high CpG contents in those regions (.65% of
total genomic CpGs), have been developed and used to study
cancer risk, tumor stage, relationship to other molecular pheno-
types and prognosis [14–18]. One study that measured 5-methyl-
cytosine content using a methyl acceptance assay in one epileptic
specimen and 10 GBM tissues showed global hypomethylation in
tumors [19]. The methylome of other cancers had showed
concurrent global hypomethylation and gene promoter hyper-
methylation [20].
This study had three primary objectives. First, we explored
differential methylation of gene promoters/CpG islands across the
genome, evaluating more than 14,000 genes at single CpG
resolution. To accomplish this goal, we used standard non
parametric and biological pathway based analytical approaches
to compare primary GBM (de novo) with a substantial number of
representative normal brain tissues. Second, we investigated
genome-wide methylation level, which included CpG methylation
levels in the repetitive elements, as potential diagnostic marker in
GBM. We characterized and compared changes in LINE1 (L1
retrotransposon), 5 methyl-deoxycytidine (5m-dC) and 5 hydro-
xylmethyl-deoxycytidine (5hm-dC). Analysis of LINE1 is widely
used as a marker of global cytosine methylation level [10,18].
Analysis of 5m-dC gives a broader and more accurate measure of
global methylation across the genome. 5hm-dC is an oxidized
product of 5m-dC generated by the a-ketoglutarate-dependent
TET dioxygenases [21]. One report showed that 5hm-dC was
strongly depleted in glioma and other cancers [21]. Third, we
evaluated the prognostic values of methylation pathways and
global methylation markers in a multi-variable Cox proportional
hazard model, adjusted for IDH1 mutation, GCIMP status, MGMT
methylation and other clinical factors.
Materials and Methods
GBM and Brain Control Tissues in the Discovery Dataset
This study was approved by the institutional review boards
(IRBs) of Columbia University (CUMC) and Case Western
Reserve University (CWRU). Participants provided written
informed consents. Primary GBMs were retrieved from each
institution’s biorepositories. All tumor tissues were snap-frozen
immediately post resection and were examined neuropathologi-
cally. Only tissues with an estimated 80% tumor nuclei and less
than 50% necrosis were accepted for DNA extraction and
subsequent methylation analyses. Fifty-four (54) de novo GBM
(40 from CUMC and 14 from CWRU) passed these criteria and
were included in this study.
Control brain tissues were obtained from the New York Brain
Bank. We retrieved 24 post-mortem, freshly frozen control tissues
from 24 unique individuals. All control tissues had been previously
examined by a neuro-pathologist and were verified to be without
pathological evidence of other neurological or psychiatric diseases.
These 24 brain controls and the aforementioned 54 GBMs
comprised the discovery dataset. The data of our discovery dataset
was deposited into GEO (accession # 50923).
GBM and Control Brain Tissues in the Validation Dataset
A validation GBM dataset was retrieved from the publicly
available Cancer Genome Atlas Data Portal (TCGA data portal).
This dataset comprised of 163 GBM samples submitted at initial
diagnoses and were analyzed with the Illumina Methylation27
platform (CWRU cases were excluded). The data were from
batches 16, 20, 26, 38 and 62, which were not included in the
previous TCGA marker paper on GBM methylation [6]. The four
control brain tissues used for that publication were not part of the
TCGA dataset and were not available for download in the TCGA
Public Portal (personal communication Daniel Weinsberger).
Instead, we retrieved 140 publicly available brain tissue controls
from GEO accession (# 15745) and dbGAP (phs000249.v1.p1) for
comparison with TCGA tumors. This cohort of control brain
tissues were obtained from consented subjects, at the time of
autopsy, at the University of Maryland, Johns Hopkins University
and the National Institute of Aging. They were examined
neuropathologically to be without any intra-cranial pathology.
The methylation results using Illumina Methylation 27 K platform
were published previously [22].
In addition to having a validation dataset, we also validated the
most significantly methylated CpG sites via pyrosequencing
experiments. We chose those top sites that not only passed our
FDR adjusted criteria but also showed at least 4 fold increased or
decreased in methylation compared to control tissues. For
correlation of validated methylation probes with gene expression,
we used the corresponding TCGA gene expression dataset for the
same 162 GBM patients (Agilent 244k Custom Gene Expression
G4502A-07) to calculate overall Spearman correlation coefficients.
DNA Methylation and Illumina Infinium Human
Methylation 27 K Platform
DNA was extracted by standard proteinase K/RNase treatment
and phenol/chloroform extraction. Bisulfite modification of 1 mg
of DNA was conducted using an EZ DNA Methylation Kit (Zymo
Research, Irvine, CA). The HumanMethylation27 DNA Analysis
BeadChips (Illumina) were used to interrogate 27,578 highly
informative CpG sites at single nucleotide resolution, covering
14,495 genes. The array hybridization was conducted under a
temperature gradient program, and the array was imaged using a
BeadArray Reader. Image processing and intensity data extraction
was performed as described previously [23].
Levels of 5m-dC, 5hm-dC and LINE1 Methylation
To determine the overall percentages of 5m-dC and 5hm-dC,
we first measured concentrations of dC, 5m-dC and 5hm-dC. We
modified a previously published method by adding determination
of 5hm-dC levels, using [15N3]-5m-dC as the internal standard for
5hm-dC and [15N3]-dC as the internal standard for dC [24].
UPLC/MS/MS positive ionization mode was used to monitor the
mass to charge (m/z) transitions of dC: 228.1R112.0; [15N3]-dC:
231.1R115.0; 5m-dC: 242-1R126.0; [15N3]-5m-dC: 245-
1R129.0 and 5hm-dC: 258.1R142.1. Standard curves were
prepared by plotting the analyte/[15N3]-labeled 5m-dC internal
Methylation in Glioblastoma
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standard ratio (M+0/M+3) against nucleoside concentration, and
the concentrations of dC, 5m-dC and 5hm-dC in each sample
were calculated. Percentages of 5m-dC and 5hm-dC were
obtained by dividing the concentrations of 5m-dC and 5hm-dC
by the total concentrations of cytidine nucleosides (dC +5m-dC
+5hm-dC).
LINE-1 DNA methylation levels were determined by pyrose-
quencing as previously described [25–27]. Each set of amplifi-
cations included bisulfite-converted CpGenomeTM (Millipore)
universal methylated, unmethylated and non-template controls.
Percent methylation within a sample was subsequently determined
by averaging across all three interrogated CpG sites. Non-CpG
cytosine residues were used as internal controls to verify efficient
sodium bisulfite DNA conversion. The inter- and intra-assay
coefficients of variation were 1.90 and 1.30%, respectively. All
samples were run blinded to tissue status.
Determination of Glioma CpG Island Methylator
Phenotype (GCIMP) Status
In both the discovery and validation datasets, we found those
probes in the Illumina 27 K array that corresponded to the
validated GCIMP markers as documented by Noushmehr et al
[6]. They were ANKRD43, HFE, MAL, LGALS3, FAS, RHO-F
and DOCK5. Although the paper documented 2 FAS markers:











Age (median, IQR*) 57 (52–66) 59 (50–67) 67 (57–80) 43 (27–59)
Women (%) 22 (40.74) 64(39.51) 11(45.83) 44 (31.43)
Ethnicity (%)
Caucasian 48 (88.89) 145 (89.51) 22 (91.67) 140 (100)
African American 2 (3.70) 9 (5.56) 2 (8.33) 0 (0.00)
Hispanic 2 (3.70) 0 (0.00) 1 (4.17) 0 (0.00)
Oriental 2 (3.70) 3 (1.85) 0 (0.00) 0 (0.00)
Unknown 0 (0.00) 5 (3.09) 0 (0.00) 0 (0.00)
Anatomical location (%)
Frontal 23 (42.59) 51 (31.48) 8 (33.33) 70 (50.00)
Parietal 10 (18.52) 27 (16.67) 7 (29.17) 0 (0.00)
Temporal 11 (20.37) 4 (26.54) 4 (16.67) 70 (50.00)
Occipital 6 (11.11) 10 (6.17) 2 (8.33) 0 (0.00)
Insula 1 (1.85) 0 (0.00) 2 (8.33) 0 (0.00)
Cerebellum 1 (1.85) 0 (0.00) 1 (4.17) 0 (0.00)
Midbrain/Pons/Medulla 1 (1.85) 0 (0.00) 0 (0.00) 0 (0.00)
Basal Ganglia 1 (1.85) 1 (0.62) 0 (0.00) 0 (0.00)
Missing information 0 (0.00) 30 (18.52) 0 (0.00) 0 (0.00)
Postmortem interval (hours) (median, IQR*) NA NA 5 (4.00–8.50) 14.5(10.00–18.00)
Clinical information
Surgery (%) NA NA NA
Biopsy 2 (3.70)
Subtotal resection 20 (37.04)
Gross total resection 32 (59.26)




None 0 (0.00) 46 (28.40)
Received combined therapy 54 (100.00) 107 (66.05)
Information missing 0 (0.00) 9 (5.56)
Treatment with Bevacizumab at disease
progression/recurrence (%)
NA NA
No 25 (46.30) 114 (70.37)
Yes 29 (53.70) 38 (23.46)
Missing 0 (0.00) 10 (6.17)
*IQR = interquartile range; NYBB = New York Brain Bank.
‘TCGA GBM cases did not include CWRU TCGA GBM cases.
# Publicly available brain tissue controls were from Brain Banks at the University of Maryland, Johns Hopkins University and National Institute of Aging.
doi:10.1371/journal.pone.0089376.t001
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Figure 1. Heat map of differential methylation in the discovery dataset. Heat map based on a set of 1864 CpG sites that significantly
segregated GBM and control brain tissues into six methylation classes in the discovery dataset. Methylation class numbers are marked inside the
annotation bar. The heat map columns represented CpG probes, and the rows are tumor and control brain samples. In the color scale, relative
hypermethlyation is denoted by a shift towards the red color, and relative hypomethylation towards blue. Neutral methylation is gray.
doi:10.1371/journal.pone.0089376.g001


















LTC4S 5q35.3 Production of leukotrienes
from arachidonic acid
0.40 0.16 20.24 8.20E-07 0.001
TNFRSF1A 12p13.31 Receptor for TNF; activate
NF-kappab
0.32 0.06 20.26 1.00E-06 0.001
TMEM71 8q24.22 Transmembrane protein localized
to the ER with unknown function
0.31 0.09 20.23 2.20E-06 0.001
CCL8 17q12 Mediates chemotactic activity
for leukocytes
0.33 0.12 20.21 2.30E-06 0.001
PYGM 11q13.1 Enzyme involved in
glycogenolysis
0.40 0.11 20.30 2.40E-06 0.001
PDCD1LG2 9p24.1 Regulates activated T cell
functions
0.48 0.17 20.31 2.50E-06 0.001
PPP1R3B 8p23.1 Regulates glycogen synthesis 0.38 0.13 20.24 2.60E-06 0.001
GUCY2D 17p13.1 Membrane guanylyl cyclases 0.40 0.09 20.31 2.70E-06 0.001
MMP14 14q11.2 Activates MMP2 and mediates
oncogenesis
0.39 0.09 20.30 2.80E-06 0.001
WNT4 1p36.12 Involves in inflammation,
development and oncogenesis
0.44 0.21 20.23 2.90E-06 0.001
*LTC4S: leukotriene C4 synthase; TNFRSF1A: tumor necrosis factor receptor superfamily, member 1A; TNF: tumor necrosis factor; TMEM71: encoding transmembrane
protein 71; ER: endoplasmic reticulum; CCL8: chemokine ligand 8; PYGM: phosphorylase, glycogen, muscle; PPP1R3B: protein phosphatase 1, regulatory subunit 3B;
GUCY2D: guanylate cyclase 2D; MMP14: matrix metallopeptidase 14; WNT4: wingless-type MMTV integration site family, membrane 4.
doi:10.1371/journal.pone.0089376.t002
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FAS-1 and FAS-2, they represented different regions of the
promoter of FAS gene in the MethylLight assay only (personal
communication, Daniel Weisenberger). The 27 K array contained
only one probe for FAS. Thus our clustering analyses used 7
instead of 8 markers to identify those GCIMP+tumors. In the
TCGA validation dataset, we also verified our list of GCIMP+
tumors with those reported in the NCI TCGA Wiki, which
maintained records of genomic analyses of GBM.
IDH1 Mutation
For GBM samples in the discovery dataset, IDH1 mutation
status was determined via pyrosequencing. The portion of IDH1
spanning codon 132 (75 bp amplicon) was amplified. Forward
primer was 59-GCTTGTGAGTGGATGGGTAAA-39 and bioti-
nylated reverse primers was 59-TTGCCAACATGACTTACTT-
GATC-39. Polymerase chain reaction (PCR) and pyrosequencing
assays were performed as previously described [28]. Pyrosequenc-
ing primer provided sequence data that included codon 131 and
the first nucleotide of codon 132 (59-GGGTAAAACCTATCAT-
CATA-39). Negative controls were run with all subjects’ samples.
Sequence data were analyzed using PyroMark Q24 software.
For GBM samples in the TCGA validation dataset, we
determined their IDH1 mutation status by examining their level
2 DNA sequencing data, which was generated using Illumina’s
Genome Analyzer (GA).
MGMT Methylation
For MGMT methylation status in the discovery dataset, we
chose pyrosequencing as the analytical method, because previous
studies showed that it provided the best prognostic value, cost
effectiveness and ease of use [29]. Seven CpG sites in the promoter
region of MGMT were selected based on previous validations, with
a Qiagen kit (PM00149702) [30]. Polymerase chain reaction
(PCR) was performed in a 25-ul reaction mix containing 50 ng of
bisulfite-converted DNA, 1x Pyromark PCR Master Mix (Qiagen),
1x Coral Load Concentrate (Qiagen), and 0.3-uM forward and 59
biotinylated reverse primers, using the cycling conditions and
amplifications as outlined previously [31]. Each set of amplifica-
tions included bisulfite-converted CpGenomeTM universal meth-
ylated (Millipore, Billerica, MA), unmethylated (whole genome
amplified DNA), and non-template controls. The sequencing
reaction and quantitation of methylation was conducted using a
PyroMark Q24 instrument and software (Qiagen). Percentage
methylation was calculated by averaging across all CpG sites
interrogated. As percentage methylation is a continuous variable,
we converted it to a binary variable using a ‘‘cutoff’’ to facilitate
clinical interpretation. There has been no established consensus
cut-off for pyrosequencing percentage values, but in normal brain
tissues, average MGMT promoter methylation ranges between
0% and 10% [29]. Thus, as reported previously, we used 14% as
the threshold to distinguish unmethylated from methylated
MGMT promoter in a given tumor [15].
Since TCGA did not separately provide MGMT methylation
level of their GBMs, we used the CpG probes on the Illumina 27
K array to determine these tumors’ MGMT methylation status.
Two validated MGMT probes, cg12434587 and cg12981137, were
used in prognostic models as a continuous variable, because a
previous study confirmed their prognostic and classification
properties [32].
Pyrosequencing Validation of Differentially Methylated
Genes
For other significant CpG sites that were differentially
methylated, the regions selected for interrogation covered the
particular CpG sites on the Illumina arrays as well as surrounding
sites. PCR and pyrosequencing assays were as described above
using Qiagen kits. Primers were included in Table S1. Percent
methylation of each gene was calculated by averaging across all
CpG sites interrogated.
Statistical Methods
Data assembly. Each methylation data point represents the
fluorescent signals from the M (methylated) and U (unmethylated)
alleles. Background intensity was computed from a set of negative
controls and was subtracted from each analytical data point. The
ratio of fluorescent signals was then computed from the 2 alleles to
reflect the fractional methylation level at each CpG site (b-value),
which is between 0 and 1 as the proportion of methylation for a
given CpG site. Beta values were generated using Illumina
BeadStudio software. For quality control, methylation measures
with a detection P value .0.05 and samples with CpG coverage ,
75% were removed (for 7 probes total). All X and Y chromosome
probes (including 1,085 in X and 7 in Y) were dropped, leaving
26,486 probes for all further analyses. We performed two major
types of analyses: 1. Locus by locus comparison between GBM and
control brain tissues; 2. Unsupervised hierarchical clustering of
tumors and control tissues.
Locus-by-locus analyses. For both the discovery and
validation datasets, we first filtered out those CpG sites with
median |Db| ,0.2, as studies in the past had shown that this
methylation array cannot accurately detect b difference at or
below 0.17 [23]. Then we used the non-parametric Wilcoxon
Rank Sum test to compare each CpG site’s methylation levels
between normal brain tissues and controls; Benjamin-Hochberg
false discovery rate (FDR) was used to adjust for multiple
comparisons. Significance level was set at FDR #0.05. Due to
influence on differential methylation by neuroanatomical region
and age, we also performed an adjusted analysis using a published
method based on logistic regression: logit (P) = mij+A*bij+B*agej+
C*locationj+eij, where P is the probability to be a tumor; b= beta
for the CpG probe i of sample j; m= intercept for the CpG i of
sample j; age = age of the patient from sample j; location = brain
location of sample j; e= error term of the CpG i of sample j [33].
Histograms were generated to show median |Db| distributions of
hyper- and hypomethylated CpG sites.
Unsupervised hierarchical clustering. To explore data
patterns, we performed unsupervised hierarchical clustering on
those differentially methylated CpG sites (FDR #0.05) using
Euclidean distance metric and Ward linkage. The same clustering
algorithm was applied to the discovery and validation datasets. To
further reduce the dimensionality of our datasets, we also used
principal component analyses (PCA) with correlation matrix for
data reduction.
Biological pathways involved in differential
methylation. Ingenuity Pathway Analysis (IPA, Ingenuity
Systems, Redwood City, CA) was used for canonical pathway
analyses of those validated, differential genes. This bioinformatics
tool was used to provide insights into the most involved biological
pathways in tumorigenesis based on DNA methylation alterations.
Correlation of global methylation markers with
methylation classes. We compared LINE1, 5m-dC and
5hm-dC levels among methylation classes using the non-paramet-
ric Kruskal-Wallis Test, as prior analyses had shown that these
markers were not normally distributed [26]. Post-hoc pairwise
Methylation in Glioblastoma
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comparisons after significant Kruskal-Wallis Tests were conducted
using the Tukey HSD test.
Survival analyses. Prognostic assessments were performed
separately for the discovery tumor dataset and the TCGA
validation dataset, using Cox proportional hazard regression
models. We investigated the value of methylation biomarkers other
than MGMT or GCIMP, such as LINE1, 5m-dC and 5hm-dC, as
potential independent prognostic factors. Moreover, biological
processes do not act through the effect of a single gene but are the
results of combined influences of many genes in a relevant
pathway. Thus we also explored the net effect of the most
important methylated pathways, such as those discovered by IPA,
as prognostic factors. To achieve this goal, we calculated an index
for a top pathway, which is a combination of the cross product of
beta values and univariable Cox regression coefficient of each
involved genes in that pathway. The index for the pathway was
then evaluated in regression models. This method was previously
published in other pathway-based survival studies using genome-
wide microarrays [34]. Standard clinical and molecular pathology
information included MGMT methylation, GCIMP status, IDH1
mutation, age at diagnoses, Karnofsky performance score (KPS) at
the time of diagnoses, extent of surgical resection, bevacizumab
use at recurrence or tumor progression and the center which
provided the specimens. In the discovery dataset, concomitant
chemo-radiation was not included in survival model, as all patients
received combined treatment. In the TCGA dataset, there was no
information on extent of surgery and no global methylation
biomarkers.
Each prognostic factor was first evaluated in a univariable Cox
proportional hazard model analyses. Those factors that reached
significance levels of p#0.1 were entered into the multivariable
Cox model. All prognostic factors in the multivariable model were
then removed one by one via backward elimination if the covariate
p value is .0.05. This process continued until covariates kept in
the model were all significant. Then the eliminated factors were
added one-by-one back into the model to ensure that they were
not significant in the multivariable model. The final model
consisted of all significant factors (p#0.05) in the presence of each
other. For each covariate, proportional hazard assumption was
tested by plotting scaled Schoenfeld residuals against the natural
log of time.
Results
Demographics of GBM Cases and Normal Brain Controls
The clinical, demographic and pathological characteristics of
GBM cases and brain controls are detailed in Table 1. Most GBM
and control tissues came from subjects over age 50. Controls from
GEO/dbGAP had median age younger than other groups. More
men than women were represented in both tumors and controls.
Frontal, parietal and temporal lobes represented the most
common anatomical locations of both tumors and control tissues.
For the group of brain controls retrieved from GEO/dbGAP,
methylation data from four brain locations: frontal, temporal, pons
and cerebellum were available. We only used frontal and temporal
brain controls for comparison with TCGA glioblastoma, because
these tumor tissues were mostly from frontal and temporal lobes.


















MTSS1 8q24.13 A putative tumor suppressor
gene in cancers
0.49 0.90 0.41 1.10E-06 0.001
LDB3 10q23.2 A PDZ domain containing
protein that regulates
ion channels
0.55 0.87 0.32 1.50E-06 0.001
HIPK2 7q34 Interacts with multiple
transcription factors
0.39 0.69 0.30 1.60E-06 0.001
PKD2 4q22.1 Involves in calcium
transport and signaling
0.55 0.80 0.26 2.30E-06 0.001
C11orf39 11q25 Function unknown 0.55 0.84 0.29 4.60E-06 0.001
Ells1 7p14.3 Involves in lysine
ubiquitylation and
proteasomal degradation
0.27 0.67 0.40 4.90E-06 0.001
C11orf2 11q13 Involves in steroid
metabolism
0.68 0.90 0.22 6.10E-06 0.001
FLJ36268 9p22.2 Located in a common fragile
site; over-expression
may lead to genomic
instability
0.51 0.79 0.28 6.40E-06 0.001
ZNF146 19q13.1 A Kruppel protein that
regulates telomere
0.57 0.79 0.22 7.50E-06 0.001
GUP1 3p22.1 Negatively regulates
N terminal protein
palmitoylation
0.43 0.75 0.32 8.20E-06 0.001
*MTSS1: metastasis suppressor 1; LDB3: LIM domain binding 3; HIPK2: homeodomain interacting protein kinase 2; PKD2: polycystic kidney disease 2; C11orf39:
chromosome 11 open reading frame 39; Ells1: chromosome 7 open reading frame 41; C11orf2: chromosome 11 opening reading frame 2; FLJ36268: chromosome 9
open reading frame 139; ZNF146: zinc finger protein 146; GUP1: hedgehog acyltransferase-like.
doi:10.1371/journal.pone.0089376.t003
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For NYBB brain controls, the frozen postmortem interval (PMI),
which was calculated from the subject’s reported time of death to
the time the brain was processed, was a median of 5 hours; this
time interval was shorter than that of 14.5 hours of dbGAP brain
controls or other post-mortem brain tissues [8,9]. Causes of death
for NYBB controls were cardiac (n = 14), pulmonary (n = 4), renal
(n = 2), trauma (n = 2), cholangiocarcinoma (n = 1; no brain
metastases) and unknown (n = 1). The causes of death for GEO/
dbGAP controls were unknown.
Differential Methylation between GBM and Control Brain
Tissues in the Discovery Dataset
Methylation in 1864 CpG sites, corresponding to 1639 genes,
differed significantly between GBM and normal brain tissues in
the discovery dataset. Unadjusted and adjusted analyses essentially
gave the same CpG list. Table S2 shows the complete list of
unadjusted, differentially methylated CpG sites in the discovery
dataset. Overall 1389 CpG sites (1175 genes) were hypomethy-
lated in the tumors relative to controls, and 475 CpG sites (464
genes) were hypermethylated. The top 10 most differentially
hypomethylated and hypermethylated CpGs are presented in
Table 2 and 3, respectively. Figure 1 shows two key features of the
unsupervised hierarchical clustering analysis. First, tumors and
controls segregated into six classes, with five classes of tumors and
one of control. Control brains did not form subgroups based on
age or tissue of origin. Class 3 is the dominant tumor class with 29
subjects. Class 5 contained four tumors that were positive for the
Glioma CpG Island Methylator Phenotype (GCIMP+). GCIMP
status was verified using the markers described by Noushemir et al
(Figure S1a). As previously reported, subjects with GCIMP+
tumors were significantly younger than GCIMP– subjects
(p = 0.007). Pyrosequencing analyses showed that five tumors
harbored mutations in IDH1: four R132H and one R132L
mutations. Four of these five IDH1 mutated tumors corresponded
to the four GCIMP+GBMs but one was a GCIMP negative tumor.
The second feature of the heatmap showed that hyper-and
hypomethylated CpG sites separated well into two respective
blocks (see columns in Figure 1). Overall, nearly 70% differentially
methylated probes were relatively hypomethylated in the tumors.
Among tumor classes, each class showed variations in the pattern
or degree of hypo and hyper methylation. Class 1 tumors
appeared to have higher degree of hypomethylation than other
tumor classes. Class 3 tumors showed the clearest transition from
hypermethylated to hypomethylated CpG blocks. Compared to
brain controls, Class 5 (GCIMP+) is only hypermethylated at
discrete loci. Figure 2a illustrates the range of values of median
|Db| in the discovery dataset. There were more hypomethylated
than hypermethylated CpGs at moderate |Db| between 0.2 and
0.49; however, hypermethylated CpGs predominated when
|Db| .0.5.
Figure 3a illustrates principal component analyses (PCA) of the
discovery dataset. The 1864 significant CpGs can be reduced to 40
orthogonal principal components (PC) that explained 95% of the
variance of the dataset, with the first three PC explained 67% of
the variance. Overall, controls clustered tightly together, whereas
GBM showed wide dispersion in space due to increase in tumor
variance. Each of the 5 tumor classes had its own elliptical plane
that is orthogonal to each other, though some members of the
classes overlapped each other at the periphery. Figures S2a shows
the top down view of PCA analyses. It illustrates the posterior
position of the GCIMP+ group, which was apart from other
methylation classes but was difficult to fully appreciate from the
frontal view.
Table 4 shows the correlations in methylation level between
MGMT and 5 differentially methylated CpG sites from the
discovery dataset using Illumina’s BeadChip and pyrosequencing
assays. Correlations overall using Spearman’s rho statistics was
Figure 2. Histograms of median |Db| distributions. a. The histogram showing a range of median |Db| of significant CpG sites from the discovery
dataset; b. the histogram of a range of median |Db| of significant CpG sites from the validation dataset. Red bars denote the number of
hypermethylated CpGs, and blue bar represented hypomethylated CpGs.
doi:10.1371/journal.pone.0089376.g002
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.0.8. Thus our results supported previous reports of excellent
validations of this methylation array technology using pyrose-
quencing [3,31].
Results of Validation Dataset and Pyrosequencing
Validation
Comparison of 163 TCGA GBMs with 140 publicly available
controls showed 2445 CpG sites (2018 genes) were differentially
methylated between GBM and normal. Table S3 shows the list of
differentially methylated CpGs. There were 1625 hypomethylated
Figure 3. Principal component analyses (PCA) of the discovery and validation datasets. a. In the discovery dataset, the 5 tumor and 1
control methylation classes were represented by the first 3 principal components (PCs) in x, y and z axes in 3 dimensional space. b. In the validation
dataset, 5 tumors and 2 control classes were represented by the first 3 PCs in 3 dimensional space.
doi:10.1371/journal.pone.0089376.g003
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CpGs (1368 genes) and 820 hypermethylated CpG sites (650
genes). Figure 4 shows the heatmap of the validation dataset,
which also demonstrates hyper and hypomethylated probes
formed two separate blocks. Tumors and controls were clustered
into 7 classes. Similar to the discovery dataset, there were 5 classes
of tumors but 2 of controls. Control subjects in Class 6 were
significantly older than those in Class 7 (p,0.03). Class 1 tumors
contained CpG sites that acquired a higher degree of hypomethy-
lation. Class 5 had 13 GBMs that were GCIMP +. Again, relative
to controls, hypermethylated CpGs were located in discrete loci.
Figure S1b showed unsupervised hierarchical clustering that
identified these 13 GCIMP+tumors, using markers as described
by Noushemir et al. Our results were also confirmed by those
reported in the TCGA Wiki. Out of these 13 GCIMP+ tumors, 6
were IDH1 mutated. Similar to the GBMs in our discovery
dataset, the distribution of median |Db| ranges showed
hypomethylated CpGs were more prevalent in the moderate
|Db| range. But at |Db| .0.5, there were more hypermethylated
probes (Figure 2b).
Figure 3b shows the PCA analysis of the validation dataset,
which reduced 2445 significant CpGs to 112 orthogonal PC that
explained 95% variance of the dataset, and the top 3 PC
accounted for 69% of the total variance. Similar to our discovery
dataset, controls clustered tightly together, whereas GBM showed
a wide range of methylation variability. Supporting Figure S2b
shows the top down view of the PCA analyses, which also
illustrates the posterior and separate position of the GCIMP+
group. The physical relationship between the two control groups is
better visualized in this view as well.
Table 4. The correlations between b values of CpG sites and corresponding mean percentage methylation levels using
pyrosequencing from our discovery dataset.
Gene Symbol
Mean pyrosequencing
level (%) Mean methylation level (b) Spearman’s Correlation (r) P-value
MGMT 31.98 0.64 0.51 ,0.00001
BHMT 55.51 0.63 0.93 ,0.0001
BST2 33.45 0.26 0.94 ,0.0001
DAB2IP 5.90 0.27 0.80 ,0.0001
DGKE 42.84 0.49 0.97 ,0.0001
PCDHGB4 35.38 0.41 0.88 ,0.0001
doi:10.1371/journal.pone.0089376.t004
Figure 4. Heat map of differential methylation in the validation dataset. Heat map based on a set of 2445 CpG sites that significantly
segregated GBM and control brain tissues into seven methylation classes in the validation dataset. Annotations were the same as Figure 1.
doi:10.1371/journal.pone.0089376.g004
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Figure 5. The most significant canonical pathways represented in our validated gene list. a. The horizontal blue bars showed the top10
significant canonical pathways that were altered epigenetically in the hypomethylated gene set, using Ingenuity Pathway Analysis (IPA). The orange
square denotes the ratio of number of genes presented in our dataset over the total number of genes in that pathway. The top horizontal axis
represents FDR (Benjamin-Hochberg) corrected P value, and the bottom one denotes ratio of number of genes presented in the dataset over the total
number of genes. The vertical dotted line (in orange) represents the threshold of statistical significance. b. The 5 significant canonical pathways
enriched in the hypermethylated gene set. Annotation is the same as the hypomethylated gene list.
doi:10.1371/journal.pone.0089376.g005
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Overall, 1548 CpG sites (1307 genes) in the validation dataset
overlapped with the 1864 CpG sites (1639 genes) from the
discovery dataset (83%). Of the 1307 validated genes, 905 were
hypermethylated and 402 were hypomethylated. These differen-
tially methylated CpGs and corresponding genes are included in
Table S4.
Out of 1307 validated, differentially methylated genes, 1130 had
available matched mRNA expression in the TCGA GBM data
files (Agilent 244k Custom Gene Expression G4502A). All 163
TCGA GBM cases had corresponding methylation and mRNA
expression data. The overall Spearman’s rho was 20.42 (95 CI
20.54, 20.29, p-values = 0.018) for hypermethylated genes, and
20.28 (95% CI 20.42, 20.13, p value = 0.043). In the set of
hypermethylated genes, 71. 89% of methylation-expression pairs
showed significant inverse correlations (p#0.05), whereas 55.36%
of hypomethylated genes-expression pairs were inversely related.
Hence, gene expression and methylation intensity were negatively
correlated for these significant genes, but correlation appeared to
be stronger for hypermethylated genes.
Biological Characteristics of Validated Genes and
Involved Pathways
IPA analyses were conducted separately for hypomethylated
and hypermethylated genes. Our results showed that the top 10
significant canonical pathways involved in hypomethylation were
all related to immune system functions (Figure 5a). In contrast,
only 5 pathways were significant among hypermethylated genes
(Figure 5b); the top one influenced embryonic stem-cell pluripo-
tency, but other significant pathways were involved ubiquitously in
cell signaling, such as cAMP and G-protein.
We then used the top two hypomethylated pathways, which are
related to granulocyte and agranulocyte adhesion and diapedesis
and created a pathway index as mentioned previously in the
Materials and Methods section. This immune index included
CXCL10, C5AR1, CCL7, MYL4, ICAM2, IL1b, MMP14, SELE,
IL18, IL1R1, MMP3, MMP19, CDH5, MYH4, ITGB2 and CCL11.
With the same method, we also created an index for stem cell
pluripotency, which was the top hypermethylated pathway. The
embryonic stem cell (EST) index included GATA4, GATA6,
NEUROG1, HOXB1, ISL1, FOXD3, GBX2 and MYF5. These
indices were later used in survival analyses (see below).
We investigated targets of polycomb repressive complex 2
(PRC2) or histone 3 lysine 27 trimethylation (H3K27me3) in
Figure 6. Enrichment of PRC2 and H3K27me3 in our validated
gene list. Venn diagram showing the frequency of enrichment of PRC2
targets (EZH2, SUZ12, EED) and H3K27me3 in embryonic stem cells from
our list of validated genes. The number of methylated genes for each
enriched target and their overlaps were represented in corresponding
areas inside the ellipses. Please note that overlapping areas are not
drawn to scale.
doi:10.1371/journal.pone.0089376.g006
Figure 7. Levels of global methylation markers among
methylation classes. a. Levels of 5m-dC between brain controls
and tumors, and among methylation classes. Red, yellow and green
lines (dotted) denoted pairwise comparison between two classes and
the P values of their comparisons. b. Levels of LINE1 between brain
controls and tumors, and among methylation classes. c. Levels of 5hm-
dC between brain controls and tumors, and among methylation classes.
doi:10.1371/journal.pone.0089376.g007
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human embryonic stem cells (hESC). To quantify the degree of
enrichment in our validated genes, we queried CHIP-seq datasets
of H1-hESC (Tier 1) in ENCODE and from published papers
[35,36]. We downloaded lists of genes that are targets of
H3K27me3 and PRC2, which included Suppressor of Zeste 12
Homolog (SUZ12), Embryonic Ectoderm Development (EED) and
Enhancer of Zeste Homolog 2 (EZH2). The resulting lists of targets
were matched to our validated gene list. Overall, 164 of 402
validated and hypermethylated genes (40.80%) were targets of at
least one of PRC2 or H3K27me3, whereas 53 of 905
hypomethylated genes (5.86%) were their targets. Hypermethy-
lated genes were enriched with PRC2 or H3K27me3 targets
(x2 = 245.42, df = 1, p = 0.0001). In total, 217 of 1307 genes
(16.60%) were targets of PRC2 or H3K27me3. Figure 6 illustrates
the frequency and overlap of enrichment of PRC2 and
H3K27me3 in our validated, differentially methylated CpG sites
using a Venn diagram.
Correlation of Methylation Classes with Biomarkers of
Global Methylation Levels
LINE1, 5m-dC and 5hm-dC levels were all significantly lower
in GBMs compared to control brain tissues (p,0.0001 for all 3
markers). However, 5m-dC level was most capable in discrimi-
nating among various methylation classes (Figure 7a). In both 5m-
dC and LINE1, global methylation levels were lowest in Class 1
tumor, and their levels successively rose from Class 1 to 5
(Figure 7a and 7b). Class 4 and 5 tumors had 5m-dC and LINE1
levels that were not statistically different from those of control
brains. With respect to 5hm-dC levels, tumors were uniformly low
compared to control tissues, but there were no differences in levels
among tumor classes. (Figure 7c).
Survival Analyses
Univariable and multivariable survival analyses results are
shown in Table 5 and 6, respectively. Overall the median survival
of the discovery population is 20.09 months (IQR: 9.11–34.39
months). In this dataset, age at diagnosis, KPS, study center
(CWRU versus Columbia), LINE1 methylation level, MGMT
methylation (50% methylated in control brains and 67%
methylated in tumors), immune index and ESC index were all
statistically significant prognostic factors in univariable analyses.
Gross total resection and methylation Class 4 and 5 (GCIMP)
showed trends towards favorable prognoses in the Univariable
Cox models. When these variables were included in a multivar-
iable Cox proportional hazards model, high level of LINE1
methylation (higher level of genomic stability), methylated MGMT,
along with high KPS and gross total resection were all significant
favorable prognostic factors. High levels of methylation in genes
Table 5. Univariable Cox proportional hazard regression results of the discovery and validation datasets.
Discovery dataset Validation dataset
Factors HR (95% CI) P value Factors HR (95% CI) P value
Age at diagnosis 1.03 (1.01–1.06) 0.006 Age at diagnosis 1.03 (1.02–1.05) 0.0001
KPS 0.94 (0.91–0.96) 0.0001 KPS 0.97 (0.95–0.98) 0.0001
Surgery Surgery
Biopsy Reference Biopsy NA
Subtotal resection 0.31 (0.068–1.40) 0.13 Subtotal resection NA
Gross total resection 0.28 (0.063–1.23) 0.093 Gross total resection NA
Bevacizumab Concomitant XRT/TMZ
None Reference No Reference
Received therapy 0.85 (0.46–1.55) 0.60 Yes 0.59 (0.40–0.86) 0.006
LINE1 level 0.93 (0.88–0.97) 0.003 Bevacizumab
5m-dC level 0.75 (0.33–1.25) 0.34 No Reference
5hm-dC level 0.95 (0.58–4.40) 0.43 Yes 0.60 (0.40–0.91) 0.017
MGMT methylation MGMT methylation
Unmethylated Reference Cg12434587 0.43 (0.19–0.99) 0.048
Methylated 0.39 (0.21–0.75) 0.005 Cg12981137 0.46 (0.23–0.92) 0.028
Methylation class Methylation class
Class 3 Reference Class 2 Reference
Class 1 0.95 (0.33–2.73) 0.92 Class 1 0.59 (0.36–0.97) 0.039
Class 2 0.65 (0.23–1.86) 0.42 Class 3 0.59 (0.35–0.99) 0.048
Class 4 0.49 (0.21–1.14) 0.098 Class 4 0.81 (0.49–1.34) 0.41
Class 5 (GCIMP) 0.28 (0.066–1.19) 0.085 Class 5 (GCIMP) 0.21 (0.065–0.67) 0.009
ESC index 1.33 (1.04–1.69) 0.024 ESC index 3.91 (1.31–11.72) 0.015
Immune index 1.22 (1.07–1.38) 0.002 Immune index 2.04 (1.28–3.24) 0.003
Participating Center Participating Center
Columbia Reference Other 10 centers Reference
Case Western Reserve University 3.68 (1.89–7.18) 0.0001 Center 41 4.10 (1.86–9.04) 0.0001
doi:10.1371/journal.pone.0089376.t005
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that affect stem cell pluripotency or promote differentiation, as
indicated by higher score of the ESC index, remained a significant
poor prognostic factor. However, age at diagnosis, GCIMP, study
center and immune index were no longer significant in the
presence of these other variables.
We found 3 factors that were strongly associated with more
advanced age at diagnoses and might have eliminated its effect in
multivariable survival analyses: 1. A higher ESC index (p = 0.001);
2. A higher immune index, which denotes less hypomethylation in
genes that control leukocyte trafficking (p = 0.032); 3. Low LINE1
methylation levels (p = 0.05). Due to our limited sample size and
only 4. GCIMP+ tumors, we were unable to confirm GCIMP’s
prognostic ability. However, GCIMP+ tumors showed strong
correlation with MGMT methylation (p = 0.017).
The median survival of the TCGA validation dataset was 14.53
months (IQR: 7.63–21.30 months). Univariable Cox model
showed that age at diagnosis, KPS, concomitant radiation with
temozolomide (TMZ), treatment with Bevacizumab, study center
41, MGMT methylation, immune index and ESC index were all
significant prognostic factors on their own. When the dominant
Methylation Class 2 was served as a reference, Class 1, 3 and 5
(GCIMP) showed favorable prognoses, with GCIMP+ group having
the best prognosis. In the multivariable model, younger age at
diagnosis, higher KPS, concomitant treatment with radiation and
TMZ and methylation Class 3 were significant favorable
prognostic factors. Higher scores of the immune index or less
degree of hypomethylation in immunity related genes, high ESC
index and study center 41 remained significant poor prognostic
factors. Of note, methylation Class 5 (GCIMP) was no longer
significant in the multivariable model. Instead, methylation Class 3
(with Class 2 as reference) showed a favorable survival after
adjustment by other covariates.
When we evaluated factors that most influenced GCIMP status
in logistic regression, younger age of onset and a lower score in the
immune index (higher degree of hypomethylation) were the
strongest factors associated with the GCIMP+ group (p = 0.03 and
p = 0.01, respectively). Thus, in multivariable survival analyses,
these 2 factors had overshadowed GCIMP as more significant
prognostic factors. Similarly, MGMT methylation level based on
probes on the Illumina array was no longer a significant prognostic
factor in the multivariable survival model. Again, high level of
demethylation in immune related genes might have accounted for
MGMT’s effect, as MGMT methylation was most strongly related
to a lower score in the immune index (p = 0.007) and also GCIMP+
status (0.01).
Based on our analyses, the ESC index is a novel pathway-based
biomarker for overall survival, and we were able to validate its
prognostic significance in the TCGA dataset. Consistent between
the two study populations, higher degree of methylation in genes
that promote differentiation of stem cells is a poor prognostic
factor. Figures 8a and 8b show the adjusted Cox survival curves
based on EST index at 25th, 50th and 75th percentiles, for both the
discovery (a) and validation cohorts (b). In both datasets, tests of
proportional hazard assumptions on all covariates did not show
any violation of this assumption.
Discussion
This study validated more than 1500 differentially methylated
sites and discovered 5 patterns of methylation changes across
tumor samples in both the discovery and validation datasets. To
our knowledge, it included the largest numbers of control brain
tissues used for the investigation of differential methylation in
glioma. The increase in brain control samples have helped us to
better detect epigenetic alterations in de novo GBM. However,
our PCA scatterplot illustrated that tumor methylation showed a
wider amount of variability compared to the variability in controls.
This finding may agree with that of another study that evaluated
139 cancer-specific differentially methylated regions (cDMRs)
using a custom Illumina bead array. The investigator showed that
differential methylation was characterized by increased stochastic
variation in methylation level within each tumor type, suggesting a
general disruption of the integrity of the cancer epigenome [33].
One feature of our differential methylation analyses is that there
were more than twice as many hypomethylated CpGs as
hypermethylated loci in the tumors. This finding is supported by
differential methylation studies in other types of cancers, which
suggested that hypomethylated loci are at least as numerous as, or
often more abundant than hypermethylated CpGs [31]. However,
hypomethylated loci, though more numerous, tended to show
more moderate b changes compared to controls, whereas
hypermethylated CpGs manifested larger changes even though
they were fewer in numbers. A reason for this phenomenon may
relate to differences in epigenetic remodeling, such as changes in
chromatin marks, which lead to gene promoter hypomethylation
Table 6. Multivariable Cox proportional hazard regression
results of the discovery and validation datasets.
Discovery dataset
Factors HR (95% CI) P value
KPS 0.94 (0.91–0.97) 0.0001
Surgery
Biopsy Reference
Subtotal resection 0.20 (0.038–1.05) 0.058
Gross total resection 0.13 (0.025–0.73) 0.02
MGMT methylation
Unmethylated Reference
Methylated 0.27 (0.13–0.60) 0.001
LINE1 methylation 0.95 (0.89–0.99) 0.048
ESC index 1.50 (1.17–1.91) 0.001
Validation dataset
Age at diagnosis 1.03 (1.02–1.05) 0.0001
KPS 0.97 (0.96–0.99) 0.0001
Concomitant XRT/TMZ
No Reference
Yes 0.53 (0.35–0.81) 0.003
ESC index 4.70 (1.45–15.16) 0.010
Immune index 2.23 (1.42–3.91) 0.005
Participating Center
Other 10 centers Reference
Center 41 2.91 (1.24–6.84) 0.014
Methylation class
Class 2 Reference
Class 1 0.73 (0.40–1.33) 0.31
Class 3 0.46 (0.26–0.83) 0.010
Class 4 0.57 (0.32–1.01) 0.054
Class 5 (GCIMP) 2.22 (0.53–9.29) 0.28
doi:10.1371/journal.pone.0089376.t006
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versus those chromatin alterations that affect hypermethylation
[37].
There were only 4 GCIMP+tumors and 5 IDH1 mutant tumors
in the discovery dataset. This supported the finding that GCIMP
and IDH1 mutations are uncommon findings in de novo GBM. In
both datasets, strong correlation existed between methylated
MGMT, or younger age of onset and GCIMP+ status, which
confirmed findings from previous investigations [2,6]. However,
hypermethylation relative to controls were found in discrete loci,
or ‘‘blocks’’ and did not appear to be uniform across all CpGs.
This may be due to the fact that brain controls were already
hypermethylated in many CpG sites. Moreover, as one recent
systematic review pointed out, there has been a lack of consensus
on the precise definition of CIMP in cancers [38].
For genes that were differentially methylated in our dataset, we
were able to demonstrate that different pathways are involved in
hypo- and hypermethylated genes. We found genes that regulate
the immune system, affecting both innate and cellular immunities,
were aberrantly hypomethylated in the tumors. Previous publica-
tions had focused primarily on gene hypermethylation; thus this
finding will hopefully prompt future studies on how immune
pathways, through epigenetic alterations, will relate to the
generation of immune-suppressive tumor environment, or the
host’s ability to detect and eliminate GBM.
Figure 8. Adjusted Cox proportional hazard survival curves based on ESC index percentiles. a. Adjusted Cox survival curve of the
discovery dataset, illustrating survival of subjects at the 25th, 50th and 75th percentiles of ESC index. b. Adjusted Cox survival curve of the validation
dataset, illustrating survival of subjects at the 25th, 50th and 75th percentiles of ESC index.
doi:10.1371/journal.pone.0089376.g008
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Our IPA canonical pathway results showed different pathways
were affected by hypermethylation. The top pathway confirmed
that epigenetic regulation was crucial to maintenance of stem cell
pluoripotency in GBM. Related to this finding is that almost 40%
of hypermethylated CpG sites were targets of PRC2 or
H3K27me3. PRC2 was up-regulated in glioblastoma stem-like
cells [39]. PRC2 targeted developmentally important genes,
induced compact chromatin, repressed expression of target genes
and maintained ‘‘stemness’’ in embryonic stem cells [40]. These
same genes were targets of hypermethylation in cancer, via
transformation from a polycomb-dependent silencing to methyl-
ation-dependent silencing during cancer development. Moreover,
it appeared that the DNA demethylating agent, 5-deoxy-aza-
cytidine (DAC) was able to reverse methylation and induce gene
expression in cancer cells that were marked by both repressive
chromatin marks (positive for H3K27me3) and methylation, but
histone deacetylase inhibitor (HDACi) was not able to re-activate
these genes [1,36]. These results indicated that hypermethylated
genes in cancer, even if they were maintained in a suppressed state
by polycomb marking, are competent to reactivate upon removal
of the methylation mark. Nevertheless, in GBM, demethylating
agents have not been considered in clinical trials because promoter
MGMT methylation is related to temozolomide (TMZ) response
[41]. Moreover, in view of the fact the genes involved in immune
system functions were hypomethylated in their promoters, and
repetitive elements of de-methylation may trigger further genomic
instability, broad-spectrum, demethylating drugs may potentially
bring on undesirable consequences and genomic instability.
Consistent with findings from other cancers, GBM also showed
global hypomethylation when compared to control tissues. Our
three biomarkers consistently demonstrated that tumors were
hypomethylated compared to control brains. Since these markers
measured cytosine methylation across compartments in the human
genome, and repetitive elements consisted of .65% of genomic
CpG sites versus 5.5% of them in promoters of protein coding
genes, demethylation in the repetitive elements may contribute to
a significant degree of global hypomethylation in GBM compared
to control tissues [42]. Nevertheless, since LINE1 and 5m-dC
levels in methylation Class 4 and Class 5 (GCIMP) were similar to
controls, the epigenetic alterations of these tumors might involve a
lesser degree of wide-spread, concomitant de-methylation of the
repetitive elements. Future studies using bisulfite next gen
sequencing will help to further define boundaries between hypo-
and hypermethylated domains in the GBM epigenome, as one
study had recently done in other cancer types [33].
The reasons for the strong and uniform depletion of 5hm-dC in
GBM were not clear. TET1, which converts 5m-dC to 5hm-dC,
has not been shown to be mutated or over-expressed in GBM.
Although it is also a global methylation marker and is closely
related to 5m-dC, 5hm-dC is enriched within the gene body,
promoters and transcription start site, whereas 5m-dC and LINE1
were primarily located in heterochromatin and repetitive elements
[43]. In the evaluation of prognostic marker, LINE1, was a
significant prognostic factor for overall survival in the discovery
dataset, even after it was adjusted for the effect of other known
prognostic factors such as MGMT methylation, extent of surgical
resection and KPS. This marker is worthy of further validation in
larger study or clinical trial, as the TCGA does not have
information on this biomarker.
We were able to show that higher ESC index score was a poor
survival factor in the discovery dataset, and the TCGA dataset
validated its prognostic significance. Thus, high levels of methyl-
ation of genes involved in this pathway may maintain these cells in
the pluripotent state and promote treatment resistance. However,
therapeutic design to re-differentiate this gene set cannot be ‘‘off-
the shelf’’ demethylating agents. The approach will have to target
other epigenetic components that promote these methylation
markers, or specific enhancers/suppressors of these genes.
Future studies may also want to elucidate factors that lead to
methylation changes in GBM, such as alteration in chromatin
states, and local DNA features. Some studies have suggested that
the presence of SINE and LINE may predispose methylation
spread into nearby gene promoters, unless certain insular DNA
elements, such as the presence of CTCF, SP1 or USF1, protect
against such spreading into downstream promoters [44–46]. This
study illustrated that repetitive element demethylation and
epigenetic alteration in gene promoters occur hand-in-hand, but
whether destabilization of repetitive elements may enhance
methylation spread into adjacent genes in GBM will need further
laboratory evaluation.
Supporting Information
Figure S1 Heat map showing unsupervised hierarchical
clustering using GCIMP markers. a. Using GCIMP
markers, four GBM subjects were found to be GCIMP+ in the
discovery dataset (red lines on the row dendrogram). They
corresponded to 4 of the 5 IDH1 mutated subjects. b. Using
GCIMP markers, 13 GBM subjects were found to be GCIMP+ in
the validation dataset (red lines on the row dendrogram). Six of
them had IDH1 mutations.
(TIF)
Figure S2 Top down views of PCA analyses. a. In the
discovery dataset, the separate, posterior location of the GCIMP+
group was best appreciated from this view; b. In the validation
dataset, GCIMP+ group occupied a similar location posteriorly.
Also, segregation of the 2 control groups was better visualized in
this view.
(TIF)
Table S1 List of pyrosequencing primers used in
pyrosequencing validation studies.
(PDF)
Table S2 The complete list of 1864 differentially
methylated CpG sites, their median b difference and
statistical significance levels from our discovery dataset.
(XLSX)
Table S3 The complete list of 2452 differentially
methylated CpG sites, their median b difference and
statistical significance levels from our TCGA validation
dataset.
(XLSX)
Table S4 A list of 1548 CpG probes and associated gene
names that were differentially methylated in both the
discovery and validation datasets.
(PDF)
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